Nucleic Acid Therapeutics CDMO Market Growth Fueled by Demand for Modified Nucleic Acids, Primers, Probes, and Oligo Services

InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global Nucleic Acid Therapeutics CDMO Market By Technology (Column-Based Method and Microarray-Based Method), Products (Standard Nucleic Acid, Micro-Scale Nucleic Acid, Large-Scale Nucleic Acid, Custom Nucleic Acid, Modified Nucleic Acid, Primers, Probes, Other Nucleic Acid, and Other Services), End-users (Pharmaceutical Companies, Academic Research Institute, Diagnostic Laboratories) Chemical Synthesis (Solid-Phase Oligonucleotide Synthesis, Liquid-Phase Oligonucleotide Synthesis) - By Trends, Industry Competition Analysis, Revenue and Forecast Till 2034"

According to the latest research by InsightAce Analytic, the global nucleic acid therapeutics CDMO market size valued at USD 2,540.9 Million in 2024 and it is expected to reach USD 8,688.2 Million by the year 2034, recording a promising CAGR of 13.2% during the period of 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1348

Nucleic acid therapeutics have become a transformative approach in the treatment of various genetic and chronic conditions, with increasing disease prevalence driving demand for DNA- and RNA-based therapies. These treatments, which are developed using deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or their derivatives, are witnessing growing clinical application, thereby fueling substantial expansion within the Contract Development and Manufacturing Organization (CDMO) sector.

To bolster capabilities in nucleic acid drug production, industry participants are actively pursuing strategic initiatives including mergers, acquisitions, collaborations, and facility expansions. A prominent example is the acquisition of GeneDesign, Inc., a leading Japanese CDMO specializing in nucleic acid therapeutics, by Ajinomoto Co., Inc. and OmniChem N.V. in December 2016. This transaction strategically reinforced the companies' presence in the nucleic acid CDMO landscape.

Market growth is further driven by rising demand for messenger RNA (mRNA)-based therapeutics, increasing global healthcare expenditures, cost efficiencies inherent in CDMO services, a growing number of regulatory approvals for nucleic acid-based drugs, and the rapid adoption of advanced nucleic acid technologies across diagnostic and therapeutic domains.

Nevertheless, the industry faces several challenges that may impede progress. Key concerns include supply chain inefficiencies, complexities in achieving targeted delivery, the need to maintain therapeutic efficacy while minimizing off-target effects, and a limited talent pool with expertise specific to nucleic acid manufacturing.

From a regional perspective, North America is projected to exhibit the most rapid growth, supported by substantial R&D investments, the emergence of innovative market players, heightened demand for nucleic acid therapies-particularly in the wake of the COVID-19 pandemic-and favorable reimbursement frameworks. Simultaneously, the Asia-Pacific region is expected to register robust expansion, driven by the increasing incidence of genetic diseases, a flourishing biopharmaceutical sector, and ongoing advancements in both medical technologies and manufacturing capabilities.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Major key players in the nucleic acid therapeutics CDMO market are Agilent Technologies, Inc., Ajinomoto Co. Inc., Bachem Holding AG., Biospring GmbH, Corden Pharma International, Danaher Corporation, Guangzhou Ruibo Biotechnology Co., Ltd., KNC Laboratories Co., Ltd., LGC Limited, Merck KGaA, Nippon Shokubai Co., Ltd., Nitto Denko Avecia Inc, QIAGEN N.V., S.T. Pharm Co Ltd, Sumitomo Chemical Co., Ltd., Syngene International Limited, Thermo Fisher Scientific Inc., Wuxi AppTec, Yamasa Corporation, Laboratorios Farmacéuticos Rovi, S.A., Sartorius AG (BIA Separations), AGC Biologics, FUJIFILM Diosynth Biotechnologies, Hanmi Pharmaceutical, Arranta Bio (Recipharm), ST Pharm, BioCina Pty Ltd., Curia Global, Inc. and Other Prominent Players.

Key Industry Developments:
• In June 2022, Merck agreed with Agilent Technologies to develop Process Analytical Technologies (PAT). Merck and Agilent Technologies are filling a void in the downstream PAT market through this partnership. Merck expands real-time monitoring and automated process control of key process parameters (CPPs) and critical quality attributes (CQAs) to downstream processing through the combination of its bioprocess portfolio with Agilent Technologies' sophisticated analytical technologies.
• In June 2022, CordenPharma expanded its xRNA capabilities at its Caponago, Italy, plant for sterile injectables. The business claims to have invested over €10 million in a new formulation, research, and manufacturing areas for Lipid Nanoparticles (LNP). The expansion will help clients go from pre-clinical to clinical development of xRNA-based treatments (mRNA, siRNA, saRNA, microRNA, etc.), accelerating the delivery of their new medicinal solutions into clinical stages and beyond.
• In Feb 2022, Recipharm has acquired Arranta Bio. The acquisition is a cornerstone of Recipharm's strategy to provide scientifically differentiated contract development and manufacturing services for ATMPs to innovative drug developers in the Biologics market. It builds on the capabilities acquired through the recently announced GenIbet transaction and the acquisition of Vibalogics.
• In June 2021, Danaher Corporation announced that it would add protein production, plasmid DNA, and mRNA services to its bulging life sciences portfolio by acquiring Aldevron. Through the acquisition, Danaher adds contract manufacturing services.
• In August 2020, Agilent Technologies Inc. announced it would extend its advanced production facility in Frederick, Colorado, that develops and produces "oligos," which are short DNA and RNA molecules used to make nucleic acid-based therapeutics. Oligos hold the potential to be used in inventing treatments for cancer, COVID-19, cardiovascular disease, rare and infectious diseases, and other conditions. The expansion has increased the current capacity for manufacturing therapeutic oligos at the Frederick site.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1348

Market Segments
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Technology
• Column-Based Method
• Microarray-Based Method
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Products
• Standard Nucleic Acid
• Micro-Scale Nucleic Acid
• Large-Scale Nucleic Acid
• Custom Nucleic Acid
• Modified Nucleic Acid
• Primers
• Probes
• Other Nucleic Acid
• Other Services
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Chemical Synthesis
• Solid-Phase Oligonucleotide Synthesis
• Liquid-Phase Oligonucleotide Synthesis

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on End-Users
• Pharmaceutical Companies
• Academic Research Institute
• Diagnostic Laboratories
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2022 to 2030
• U.S.
• Canada
Europe Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2022 to 2030
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2022 to 2030
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2022 to 2030
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2022 to 2030
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Read Overview Report- https://www.insightaceanalytic.com/report/global-nucleic-acid-therapeutics-cdmo-market/1348

Why should buy this report:
 To receive a comprehensive analysis of the prospects for global Nucleic Acid Therapeutics CDMO market
 To receive industry overview and future trends of global Nucleic Acid Therapeutics CDMO market
 To analyse the Nucleic Acid Therapeutics CDMO market drivers and challenges
 To get information on Nucleic Acid Therapeutics CDMO market size value (US$ Mn) forecast till 2030
 To get detailed information on major Investments, Mergers & Acquisition in global Nucleic Acid Therapeutics CDMO market industry

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.